Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
During their development and progression tumors acquire numerous mutations that, when translated into proteins give rise to neoantigens that can be recognized by T cells. Initially, neoantigens were not recognized as preferred targets for cancer immunotherapy due to their enormous diversity and the...
Main Authors: | Thomas C. Wirth, Florian Kühnel |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-12-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01848/full |
Similar Items
-
The Role of Neoantigens in Cancer Immunotherapy
by: Yueting Zhu, et al.
Published: (2021-08-01) -
Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
by: Daniel J. Verdon, et al.
Published: (2021-08-01) -
Cancer neoantigen: Boosting immunotherapy
by: Peijia Xu, et al.
Published: (2020-11-01) -
Mutation-Derived Neoantigens for Cancer Immunotherapy
by: John C. Castle, et al.
Published: (2019-08-01) -
Targeting neoantigens for cancer immunotherapy
by: Xuan Zhao, et al.
Published: (2021-07-01)